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Abstract
Over the last years, an important development has allowed the scientific community to
address a precise and accurate modification of the genome. The first probe of concept
appeared with the design and use of engineered zinc-finger nucleases (ZFNs), which was
expanded later on with the discovery and engineering of meganucleases and transcrip‐
tion activator-like effector nucleases (TALENs) and finally democratized and made easily
available to the whole scientific community with the discovery of the clustered regular‐
ly interspaced short palindromic repeats (CRISPR)/Cas9 nuclease combination technol‐
ogy. The availability of these tools has allowed a precise gene editing, such as knockout
of a specific gene or the correction of a defective gene by means of homologous recombi‐
nation (HR), taking advantage of the endogenous cell repair machinery. This process was
already known and used but was inefficient—efficiency that has been increased more
than 100-fold with the addition of the mentioned specific nucleases to the process. Apart
from the proper design of the nucleases to recognize and cut the selected site in the cell
genome, two main goals need to be adequately addressed to optimize its function: the
delivery of the tools into the desired cells and the selection of those where the gene editing
process has occurred correctly. Both steps can be easily solved when the source of cells is
extensive or can be expanded and manipulated in vitro extensively, such as immortal‐
ized cell lines or pluripotent stem cells (embryonic stem cells and induced pluripotent
stem cells). However, both steps are critical in the case of primary cells, such as the
hematopoietic stem cells (HSCs). HSCs are a rare cell population present in the bone
marrow (BM) of higher mammals, and it is the responsible for the maintenance and
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replenishment of all hematopoietic cells for the lifespan of the animals by means of two
fundamental properties: self-renewal and multipotency. HSC population is then the ideal
target for the correction of hematopoietic genetic diseases and also for the knockout of
the responsible genes to in vitro and in vivo model those hematopoietic diseases. This rare
population cannot be expanded and its in vitro manipulation and culture negatively affects
their fundamental properties of self-renewal and multipotency. These factors challenge
the application of gene editing to HSCs. Important efforts are now ongoing trying to
optimize the protocols of gene delivery and selection for HSCs. This chapter will review
and discuss how researchers are trying to solve them, all attempts that are ongoing and
the potential application of the technology to the patients affected with hematopoietic
genetic diseases.
Keywords: hematopoietic stem cells, hematopoiesis, genetic disease, gene therapy,
gene editing, nucleases, zinc finger, TALEN, meganucleases, CRISPR/Cas9
1. Introduction
Adult hematopoietic stem cells (HSCs) are a rare population of cells that are present in the bone
marrow (BM) and are the responsible for the generation of all mature blood cells, including
erythrocytes, platelets, and immune cells (1). This population represents less than 0.1% of the
total BM and is the only one capable of self-renewal, being responsible for the maintenance of
the lifelong hematopoiesis. Since their definition at the beginning of the last century (2), an
extensive knowledge of this population has been accumulated, being probably the best known
adult stem cell. HSCs can be phenotypically and functionally characterized and can be purified
and even manipulated in vitro. Once transplanted back into the animal or human body, HSCs
are capable of regenerating the whole hematopoietic system of the organism (1,3). These
capabilities established the possibility of BM transplantation as a therapeutic strategy for the
treatment of hematopoietic diseases, either inherited or acquired. BM transplantation can be
autologous, when the HSCs come from the same person, or allogeneic, when they come from a
healthy donor. Allogeneic BM transplant is the only curative treatment for oncogenic diseases
and for inherited (genetic) diseases, providing healthy HSCs. However, the immune reaction
of the transplanted cells against the recipient [graft-versus-host disease (GVHD)] and the
availability of compatible BM donors reduce dramatically its applicability and increase the
severe adverse effects of the treatment (4). To definitively solve this problem, the genetic
modification of the autologous HSCs to restore the genetic defect or to provide them with new
capabilities, the so-called gene therapy, appeared as an additional therapeutic option avoid‐
ing GVHD and providing repaired/cured cells.
The idea of gene therapy appeared up in the middle of the 20th century, when the use of
modified viruses as vectors to introduce the desired genetic material into the desired cells was
already mentioned and demonstrated as a proof-of-concept (5). Since then, gene therapy has
been playing in a roller coaster with tremendous improvements and successes but also with
serious problems that have been dramatic in some instances (6). Finally, gene therapy is
nowadays established as a real therapeutic option for a number of hematopoietic inherited
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diseases, such as immunodeficiencies or hemoglobinopathies (7). The use of self-inactivating
lentiviral vectors, the improvement of the in vitro culture conditions of the human HSCs, and
the better knowledge of HSC engraftment in the recipient has contributed to this reality (8).
Nevertheless, HSC gene therapy still has some drawbacks that needed to be addressed to make
this strategy safer. The most important one is the potential insertional mutagenesis that could
derive in an oncologic problem due to the inability to control the insertion site of the genetic
material using the present available tools (8).
Precise gene editing using the gene repair cellular machinery appeared as the next step to
follow. Widely used in the generation of animal models, mainly fish and mouse, its application
as a therapeutic option in humans was far to be considered due to the low efficacy and the
difficulty to select those cells where the desired gene edition had taken place. The discovery
of enzymes and biological systems able to cut in one precise and specific sequence of the
genome (nucleases and nuclease systems) and activate the endogenous DNA repair pathways
has clearly approached gene editing to be considered as a potential therapeutic approach in
the near future. First tested for their therapeutic potential for hematopoietic genetic diseases
in induced pluripotent stem cells (hiPSCs) (9), the principal bottleneck in these experiments
was the generation of functional HSCs from the edited hiPSCs. Thus, an increasing number of
laboratories, including ours, are now adapting the gene editing protocols to adult HSCs.
Important steps, such as the delivery of the gene editing tools, improving protocols to maintain
HSCs in vitro to allow their proper edition, and improving systems to select properly edited
cells, are important barriers that need to be overcome to definitely apply gene edition-based
gene therapy to the clinics. Some of the steps that are now being taken are explained below.
2. Hematopoiesis and hematopoietic stem cells
The hematopoietic system is responsible for the production and maturation of the different
components of the blood in a process called hematopoiesis. Blood is one of the most active
regenerative tissues, with approximately 1 trillion mature cells arising daily in adult human
BM (3). The hematopoiesis is a highly hierarchically organized structure in which all types of
mature blood cells are generated from a small subpopulation of undifferentiated cells allocated
in the BM. The hematopoietic system is divided in two main different lineages: lymphoid and
myeloid. The lymphoid lineage gives rise to the T cells, B cells, and natural killer (NK) cells,
whereas the myeloid lineage formed granulocytes, monocytes, erythrocytes, and megakaryo‐
cytes/platelets (1). Different organs and tissues are implicated in the production and homeo‐
stasis of the hematopoietic systems, such as blood, BM, liver, spleen, thymus, and lymph nodes.
HSCs are the most primitive cells in the hematopoietic system and support all the hemato‐
poiesis. They are characterized by their capability to self-renew and to produce all types of
mature blood functional cells. These cells persist throughout adult life, maintaining their
hematopoiesis (1). Hematopoietic committed progenitor cells, the next step in the hemato‐
poietic differentiation process, arise from the HSCs. These cells have a higher proliferative
activity than HSCs, a limited self-renewal capacity and the ability to differentiate a limited
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number of mature cell types. Finally, mature cells complete the pyramid structure of the
hematopoiesis. These cells are characterized by a recognizable morphology, full functional
capabilities, and a low or null capacity of proliferation and self-renewal (10).
The study of human HSCs began with the identification of colony-forming progenitors using
in vitro CFU-C assays (11–14). Nowadays, human HSC capacity is usually tested in xenogeneic
transplants, in which human HSCs are transplanted in immunodeficient mouse strains that
have a permissive microenvironment for the human HSC engraftment (15). The first human‐
ized mouse model was the severe combined immune-deficient (SCID) mouse lacking B and T
cells (16,17). Then, different mouse models were developed based on their ability to efficiently
support high levels of all lineages of human engraftment (18–20). The CD34 marker was
identified as a relevant indicator of human hematopoietic progenitors, which includes HSCs
(21,22); nevertheless, due to the variability in their repopulation ability, several subpopulations
of HSCs were identified in xenograft models, some subpopulation with a transient and limited
ability to support the hematopoietic system, such as short-term HSCs (ST-HSCs), multipotent
progenitors (MPP), committed progenitors, or long-term HSCs (LT-HSCs), which are able to
maintain a durable hematopoiesis (23,24).
Only 1 in 106 in human BM is a transplantable HSC (25); thus, the scarcity of HSCs has led to
the necessity to purify the HSCs from the heterogeneous bulk population to allow their
handling and manipulation. The purification of HSCs requires the detection of several cell
surface markers. There are several markers whose expression is gained or lost during the
differentiation process. In mice, HSCs do not express lineage markers (myeloid or lymphoid),
so they are called lineage negative cells. In addition, HSCs express high levels of the stem cell
antigen 1 (Sca-1) and c-Kit (CD117) marker (Figure 1). These cells are called LSK cells (lineage
negative, Sca-1 positive, c-Kit positive) (1,26,27). As in mice, the absence of all lineage markers
(Lin-) determines human HSCs (28). As previously mentioned, CD34, expressed on 0.5% to 5%
of all blood cells, was the first marker found that identifies human LT-HSCs and more
differentiated progenitors (29). Later on, other markers were described in LT-HSCs such as the
expression of the CD90 (Thy1) (30) or the lack of expression of CD45RA and CD38 (found to
be expressed in more differentiated progenitors) (31–33). Moreover, integrin CD49f (involved
in cell attachment to the extracellular matrix) was shown to be expressed in LT-HSCs (34). With
respect to ST-HSCs or MPP, the loss of Thy1 and CD49f expression was proposed to be a key
signature through a more differentiated state (3). Consecutive studies have classified the
different populations depending on the expression of alternative markers, such as the expres‐
sion of aldehyde dehydrogenase (ALDH), and other surface markers, such as CD117 or CD133
(35).
3. Gene correction of hematopoietic stem cells by addition strategies and
their drawbacks
Gene therapy can be achieved by the delivery of genetic material into cells affected by a disease,
and it can be accomplished by the addition, substitution, or alteration of the related genes (8).
These modifications can be carried out by in vivo direct infusion of a vector having the ectopic
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therapeutic gene or by ex vivo manipulation of patient’s cells and their reinfusion into the
patient. Gene therapy has become a feasible and attractive alternative therapeutic strategy for
several diseases, from inherited hematopoietic, immune, and nervous diseases, including
primary immunodeficiencies, leukodystrophies, thalassemias, hemophilias, and retinal
dystrophies to cancer and other malignancies (36). In the case of blood-related diseases, HSCs
have long been the preferred target for ex vivo gene therapy due to the feasibility to isolate
them ex vivo, genetically correct them and reinfuse them through intravenous infusion (37,38).
The correction of HSCs is a promising therapeutic approach that can provide a steady and
stable expression of the transgene, restoring the function of the malfunctioning gene in the
patient. Stable expression of the transgene can be obtained by addition gene therapy using
vector-mediated transgene insertion (Table 1).
Disease Vector Patients Conditioning
regime
Target cells Transduced
cells
Outcome Adverse
effects
References
ADA γ-RV Italy (18),
USA (16)
Busulfan Lymphoid
cells and NK
cells
HSCs Transient or no
clinical benefit.
Three patients
with clonal
expansion with
long-term
efficacy
followed by
inactivation of
the transgene
No (41,151–
153)
UK (8) Mephalan or
busulfan
SIN-LVUK (10), USA
(10)
Busulfan Unpublished,
ongoing
No —
Figure 1. Human and mouse hematopoieisis. Similarities in terms of antigen differentiation markers.
Gene Editing in Adult Hematopoietic Stem Cells
http://dx.doi.org/10.5772/62383
101
Disease Vector Patients Conditioning
regime
Target cells Transduced
cells
Outcome Adverse
effects
References
SCID-X1 γ-RV UK (11),
France (11),
USA (3)
None Lymphoid
cells and NK
cells
HSCs Significant T-
reconstitution/T-
ALL in 5
patients, 1 dead
Yes (40,42,47,15
4–157)
SIN γ-
RV
UK, France,
USA (9)
None Reconstitution
of functional T
cells but at low
number
No (158–160)
LV USA Busulfan Ongoing —
CGD γ-RV USA (10),
and (3)
None or Busulfan Neutrophils HSCs No benefits Yes (43,161–
168)
Germany (2)/
Switzerland
(2)
Busulfan Long-term
correction 4/4
UK (4) Melphalan Transient
correction
Korea (2) Busulfan
+fludarabine
Short-term
correction
SIN γ-
RV
Germany Busulfan Ongoing —
LV UK,
Switzerland,
Germany,
France, USA
Busulfan Ongoing —
SCD SIN LVUSA Busulfan Ongoing —
MLD SIN LVItaly (9) Busulfan Macrophages
and microglia
HSCs No symptoms
or just milder,
after the age of
symptom onset.
Ongoing
No (86)
WAS γ-RV Germany (10)Busulfan Lymphoid
cells, NK cells,
and platelets
HSCs 9/10 with
benefits
Yes (169,170)
SIN LVUK, USA,
France, Italy
(4)
Busulfan
+fludarabine
4 with benefits,
ongoing
No (48,171,172)
β-
Thalassemia
SIN LVUSA, France
(4)
Busulfan Erythroid
cells
HSCs Therapeutic
benefit.
Ongoing
No (173)
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Disease Vector Patients Conditioning
regime
Target cells Transduced
cells
Outcome Adverse
effects
References
USA Busulfan Ongoing
FA SIN LVUSA None Ongoing —
Spain None* Ongoing —
X-ALD SIN LVLondon,
France
Busulfan and
cyclophosphamide
Macrophages
and microglia
HSCs Therapeutic
benefit.
Ongoing
No (174)
USA, France
(4)
Table 1. Addition gene therapy attempts and their outcome.
Classically, viral vectors, based on γ-retroviruses (γ-RV) or lentiviruses (LV), have been widely
used for this purpose because they ensure high transduction efficiency and long-term expres‐
sion of the transgene. γ-RVs were widely used in the first gene therapy trials that started at
the end of the 1990s (39). In diseases affecting the hematopoietic system, these vectors were
first used for the treatment of two inmunodeficiencies: adenosine deaminase deficiency (ADA)
and X-linked severe immunodeficiency or γ-chain immunodeficiency (X-SCID1) (40–42). In
the case of ADA, γ-RV-transduced autologous stem cells have been used to treat 38 patients
in three independent studies (39). Overall survival resulted in 100% at 3.5 years follow-up, and
from these, 20 patients no longer required enzyme replacement therapy. Ex vivo gene transfer
in ADA patients, by means of γ-RV, demonstrated to be efficient, as the engraftment of
corrected cells was maintained over time and resulted in the improvement of the cellular and
humoral immune response despite the mild conditioning applied (39). Similarly, the treatment
of X-SCID1 was initiated in two different clinical trials. Similar to ADA gene therapy trials, the
gene complementation of γ-chain with γ-RV was clearly efficient (42). Seventeen of the 20
treated patients showed a full or nearly full correction of the T-cell defect (39). However,
whereas, in ADA patients treated by gene therapy with γ-RV, no adverse effects related with
the genotoxicity of the procedure were observed, in X-SCID1 patients, 5 of the 20 treated
patients suffered T-cell leukemia after 2.5 to 5 years after the treatment due to insertional
mutagenesis (39). Viral insertion produces insertional mutagenesis and can induce the
activation of neighboring genes, as proto-oncogenes, through enhancer/promoter sequences
present in the retroviral long terminal repeats (LTRs). Both γ-RV and LV contain LTRs that are
present at both the 5′ and 3′ ends of retroviral RNA genome and are required for the integration
of the provirus into the host genome. Similar issues arose sometimes after the treatment of
other immunodeficiencies as the Wiscott-Aldrich syndrome, in which restored expression of
the WASP gene was achieved, but 4 of 10 treated patients were reported to suffer from
leukemia or chronic granulomatosis disease (CGD) in which the appearance of myelodys‐
plastic syndrome in 3 patients also proved to be the result of the up-regulation of genes such
as MECOM and PRDM16 in CGD patients (43–47). These severe adverse effects limited the
application of gene therapy to patients. A strong effort of the scientific community was
required to increase the safety characteristics of the vectors. The inactivation of the U3 region
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in the 3′ end of the viral genome, leading to self-inactivating (SIN-LTRs) vectors (48), and the
use of more physiological and/or specific promoters (49) were characteristics implemented in
the new improved integrative vectors. Moreover, the analysis of insertion patterns demon‐
strated that γ-RV preferentially integrate near the transcriptional start sites and promoter
regions (50), whereas this in LV occurs along transcriptionally active genes (51–53). Even so,
some studies have reported that LV produce aberrant spliced transcript and deregulated
expression in the integrated genes, although this phenomenon has not been reported in
patients (54–56). Therefore, the SIN LTRs and the integration-site preferences of LV have been
shown to substantially mitigate the insertional genotoxicity, making LV a reliable therapeutic
option. In fact, a significant number of phase I/II clinical trials are currently being conducted
with LV, which have reported remarkable efficacy and safety in immunodeficiencies, β-
thalassemia, adrenoleukodystrophy, or metachromatic leukodystrophy (36). All these HSC-
based gene therapy clinical trials have reported stable and high level of reconstitution of the
hematopoiesis of the treated patients. Besides, there has been no report of adverse events
related with LV, although the overall follow-up of some of these trials is still limited.
Nonetheless, the potential risks already observed with γ-RV could be still present. Future trials
should overcome the efficient delivery of the new genetic information in the target cells,
without altering or disrupting the host cell genome and preserving the characteristics of the
transduced cells. The uses of LV that do not require integration or the precise control of the
site where the genetic material is going to be inserted in the host genome (gene editing) are
strategies that are nowadays being explored in deep. Important efforts are invested in this
second approach that will overcome the majority of the potential adverse effects described
above. However, additional challenges need to be overcome yet.
4. Gene editing strategies in HSCs
Gene editing describes the new technology able to accurately modify genes, either by knocking
out these genes or by inserting or substituting specific sequences in a precise way. This new
technology is based on promoting the action of endogenous DNA repair pathways at the target
sequence without altering any other place in the genome. The main approach used for gene
targeting is based on the natural HR DNA repair mechanism of the cell. Homologous Recom‐
bination (HR) is an accurate DNA repair mechanism that uses the sister chromatic as a template
to repair double-stranded breaks (DSBs). HR-based gene therapy strategies started in 1980s
using DNA donors flanked by long arms with homology to the target locus (57). However, the
probability of inducing the specific insertion in the target site was low, around 10-6 (58), making
this procedure only feasible for basic research. Trying to improve this low efficiency, several
strategies have been addressed. The most important one is the development of engineered
nucleases able to induce DSBs in the specific target site, with the consequent activation of the
HR, and the gene edition in a precise place of the genome.
Although transfer of designed nucleases together with a donor template can increase the
efficiency, HR is not as frequent as other DSB repair mechanisms, such as non-homologous
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end-joining (NHEJ). This is an error-prone mechanism that binds the two DNA ends originated
in the DSB, without the use of any template. Insertions and/or deletions (INDELS) can be
introduced in the target site. HR process is more frequent during the S and G2 phases of the
cell cycle, so it takes place more frequently when cells are proliferating, and its permissiveness
varies between cell types (59).
There are different applications based on these two DNA repair mechanisms. If NHEJ takes
place, the generated INDELs could have a particular application for the stable disruption of
specific target genes (59). When HR takes place, three strategies of gene editing can be
envisaged:
• Gene correction: One or more bases from the mutated original strand are replaced by the
integration of the corrected ones. This strategy is the one to be chosen when the objective is
to introduce or repair point or small mutations. If the mutations causing the disease are not
recurrent or are produced in different genes, it will be restricted to a limited number of
patients.
• Knock-in: A partial cDNA of the gene of interest is introduced in its former locus. Usually,
a splicing acceptor is located before the cDNA to anchor the endogenous splicing donor.
Endogenous elements of the locus will control the expression of the endogenous/exogenous
chimeric cDNA/gene. Necessary to maintain the endogenous regulation of transgene.
• Safe harbor integration: It consists on the insertion of a whole expression cassette (promoter,
transgene and regulatory signals) in a concrete place of the genome. This approach could
be used for mutations produced in the same gene and also for mutations produced in
different genes.
5. Gene editing tools applicable to the gene editing of hematopoietic
stem cells
Different systems have been developed to lead the genetic modification to a specific locus.
These gene editing tools have been inspired by natural systems, which evolved over millions
years to modify DNA, among which the capability of generating DSBs has been selected for
different purposes including DNA repair or cell response against foreign DNA from patho‐
gens. The proteins involved in DSBs act by the specific hydrolysis of the DNA and are known
as nucleases. These nucleases have been described in all branches and life species. As long as
these proteins have been described, they have been rapidly applied as tools for gene editing.
Four different types of nucleases have been more widely applied to generate DSBs: homing
endonucleases (also called meganucleases), zinc-finger nucleases (ZFNs), transcription
activator-like effector nucleases (TALENs), and clustered regularly interspaced short palin‐
dromic repeats (CRISPR)/Cas9.
5.1. Meganucleases
Meganucleases tend to be small proteins (<40 kDa) encoded by mobile inteins or introns. These
families of proteins have evolved to target sequences (14–40 bp) in a specific way (60,61). In
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nature, meganucleases propagate their own introns cleaving cognate intronless alleles and
therefore producing HR. For that capability of moving its genetic sequence in a determined
place, meganucleases are also called homing endonucleases. There have been described five
families of meganucleases: GIY-YIG His-Cys box, HNH, LAGLIDADG, and PD-(D/E) XK. The
largest family is known as LAGLIDADG, named after the consensus sequence of its catalytic
motif LAGLIDADG. It is a diverse group of enzymes present in fungal and protozoan
mitochondria, plants and algae chloroplasts, bacteria, and Archaea. This family is defined for
having either one or two copies of LAGLIDADG motif acting therefore as separated monomers
or homodimers, respectively. However, meganucleases are limited as gene editing tools due
to the necessity of finding large palindromic DNA targets (62). Moreover, its design requires
important bioinformatics, difficult protein engineering, and in vitro testing.
5.2. ZFNs
In 1996, Chandrasegaran et al. started to use hybrid nucleases which combined the cleavage
domain of FokI nuclease and the specificity of Cys2His2 zinc-finger protein domains, making
possible the specific DNA cut in a sequence of more than 18 bp (63,64). FokI is capable of
generating DSB when dimerized, so to use it as a gene editing tool, two monomers must be
designed and delivered separately. Designing the two monomers in inverted orientation
improved the nuclease efficiency (65). The specific domain that binds to the DNA is formed
by tandem repetitions of Cys2His2, which form the ββα structure folded for the presence of a
Zn2+ ion. The α-helix recognizes a specific DNA triplet. Between 3 and 6 of these motifs, which
are separated by some spacer nucleotides, are modularly assembled in each monomer.
Between the recognition sites of both strains remains a small nontargeted region called
“spacer” surrounded by the FokI dimer (66–68). To avoid some off-target events already
described (69,70), monomers of two different FokI domains, only active when forming
heterodimers, have been designed (71,72). Although different ZFN open-source libraries have
been developed, the design still results complicated for nonspecialists (73,74). However, ZFNs
have been the first described nucleases and are the only ones already in clinical trials (https://
goo.gl/M0ZWoB).
5.3. TALEN
TALEN technology follows the same rationale as ZFN, the use of FokI domain because of its
nonspecific cleavage capability fused to a domain that confers DNA-binding specificity. As in
the case of ZFN, the FokI region requires dimerization to be active, so this tool also requires
the use of two monomers (65,75). In TALEN, the specificity is provided for protein domains
from TALE. TALE are bacterial proteins, first described in Xanthomonas, capable to modify the
gene transcription of the plants that these bacteria parasite (76). This DNA-binding domain is
formed by 10 to 30 repetitions of 30 residues. The 12th and 13th positions, the so-called repeat-
variable di-residues (RVDs), are the polymorphism responsible of the specificity (77). Each
RVD pair is able to recognize specifically a base pair (77–80). Knowing the code TALE-to-DNA
(79), the designing has become a relatively easy task (81). Moreover, due to the long DNA
sequences they recognize, they show the lowest off-target cleavage. On the contrary, their
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highly repetitive structures make these sequences hard to package into viral vectors because
of their tendency to recombine (82).
5.4. CRISPR/Cas9
The CRISPR/Cas9 system is the latest nuclease that has appeared in the gene editing tool arena.
CRISPR/Cas9 is part of the adaptive immune system of bacteria and Archaea. In nature, this
system cleaves foreign DNA to avoid cellular threats such as viral attacks (83,84). Up to 10
CRISPR/Cas9 systems have been described, but the type II CRISPR/Cas9 is the most used in
gene engineering to generate DSBs for research.
This strategy is based in three elements: the Cas9 nuclease, the trans-activating CRISPR RNA
(tracrRNA), and the CRISPR RNA (crRNA). Cas9 is a nuclease that produces DSBs, thanks to
its two catalytic regions, Ruv and HNH. Cas9 recognizes the tertiary RNA structures that the
duplex tracrRNA and crRNA form when they are bound to the DNA. The tracrRNA is a fix
structure that binds Cas9, the catalytic element, to the crRNA, the element that gives the
specificity to the target site. The crRNA is a 20-bp-long RNA strand complementary to the
target region. The only restriction of the system is that the target sequences must be followed
downstream for the 3-bp-long protospacer adjacent motif (PAMs), 5′-NGG-3′ (72). PAM motif
is frequent along the DNA, so CRISPR/Cas9 system crRNA can be design against almost every
DNA region. To facilitate its use, crRNA and tracrRNA have been combined in one single
molecule called single guide RNA (gRNA) (85). Thus, only two elements must be delivered
into the cells, the Cas9 and the gRNA, instead of three. Although controversial, some studies
have reported a higher off-target activity than other nucleases (86). CRISPR/Cas9 system is
developing fast and new Cas proteins recognizing different PAM sequences, having smaller
protein sizes or even been able to cut in an overhang way have been described over the last
year (87–89). Moreover, Cas9 protein modifications, as ZFN and TALE, have allowed not only
the generation of DSB but also as function as DNA activators, DNA repressors, or DNA tracers
(90).
6. Delivery of gene editing tools to HSCs: the main challenge
One of the most important steps to consider when performing a gene editing strategy is the
delivery of the gene editing tools. In fact, nowadays this is probably the main bottleneck in
gene therapy in general and definitely in the gene editing of HSCs (91).
The main objective of delivering the nucleases effectively in cells is to promote a hit-and-run
activity of the enzyme that allows a short-term boost of expression that leads to a specific
generation of a DSB in a short period of time to avoid toxicity and off-target activity due to the
long-term expression of the nuclease. In case of performing a gene addition/gene correction
strategy, we should also consider the delivery of the DNA molecule carrying the desired
sequences to be integrated in the cell genome, the so-called donor DNA molecule. Taking all
these facts into account, the delivery of gene editing tools can be classified in two different
groups: viral and nonviral transfection methods (Figure 2).
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Concerning the nonviral transfection methods, the gene editing tools can be delivered as
plasmid DNA, in vitro transcribed mRNA, or purified proteins. The delivery of plasmid DNA
is a widely used standard technique (92,93), as this molecule is easily engineered and easy to
handle. Both gene editing tools and donor sequences can be transfected in this way. The donor
sequence can be a linear donor sequence with less than 50 bp of homology (94), as well as
single-stranded DNA oligonucleotides (95), especially when inducing mutations or corrections
at the target site. Due to the negative charge of both plasmid DNA and the cell surface, the
uptake of DNA into the cells is restricted, and the delivery needs to be supported by com‐
plexing DNA with chemicals such as calcium phosphate, coat lipids, or cationic polymers (92)
or by subjecting the cells to an electric field that open pores in the nuclear and/or plasmatic
membrane of the cells (electroporation). Another important factor to take into account is the
target cell. In our case, the HSC is a hard-to-transfect cell. The only technique available
nowadays to introduce these tools inside this cell type is nucleofection. Nucleofection is an
electroporation-based transfection method that enables transfer of nucleic acids into difficult-
to-transfect cells by applying a combination of electrical parameters with cell type-specific
reagents. However, this process produces high cellular toxicity and even cell death depending
on the plasmid size and the total amount of transfected DNA. Moreover, the delivery of
plasmid DNA could mediate its random insertion into the genome of treated cells (96). The
risk of random plasmid integration mainly depends on the plasmid quality, but it is also
influenced by specific properties of the targeted cells, including the prevalence of DSBs and
the status of their DNA repair pathways. Plasmid integration, although is a nonusual event,
represents an obstacle for gene targeting approaches, as mentioned above for the more
conventional retroviral vector delivery systems.
Alternative platforms to deliver nucleases have been explored, such as the transfection of in
vitro-transcribed mRNA (97,98). The main advantage is that mRNA establishes a short-term
boost of enzyme activity with low toxicity and no risk of integration (99). Thus in vitro
transcribed mRNAs that encode ZFNs, TALENs, or Cas9 and gRNAs are the preferential forms
in which these nucleases are nucleofected into HSCs. Another possibility is to deliver nucleases
as proteins; this approach presents the same advantages as mRNA delivery, as they also act
in a hit-and-run fashion. Genetic fusion of recombinant proteins to positively supercharged
moieties favors their uptake by cellular internalization mechanisms (100,101). However,
generation of high yields of soluble and active protein transduction domains (PTDs)-contain‐
ing nucleases is difficult (102). An alternative strategy consists on the chemical conjugation of
nucleases to PTDs for receptor-mediated endocytosis (103). Interestingly, due to the positive
charge of their Cys2-His2 zinc-finger motifs, ZFNs display an intrinsic cell-penetrating capacity,
which can lead to targeted mutagenesis (102). Other delivery options under investigation
include protein transfection procedures such as electroporation (104). It has been successfully
applied in the case of CRISPR/Cas9 nucleases, where HSCs have been efficiently edited by the
direct nucleofection of the Cas9 protein/gRNA ribonucleoprotein complex (105). Chemical
transfection agents are also being investigated for nucleases as proteins (106).
Apart from nucleofection, nonintegrating viral vectors, such as integrase-deficient LV vectors
(IDLVs), adenovirus vectors (AdVs), and adeno-associated virus vectors (AAVs), also serve
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as a robust source to facilitate the delivery of the genes encoding programmable nucleases both
in vitro and in vivo in cell types that are sensitive to transfection such as HSCs (107). The decision
whether to use one type or another relies on the size of the transgene to deliver and on the
capability of the virus to transduce quiescent or diving cells.
AdVs are double-stranded DNA viruses capable of packaging up to 37 kb of DNA. However,
the transduction capacity of these vectors is highly dependent on the cellular type. Owing to
the large cargo size that can be accommodated in adenoviruses, they are an attractive platform
for the delivery of programmable nucleases and donor DNA. They have been used in some
gene targeting approaches to deliver nucleases in both fibroblasts and CD4+ T cells (108,109),
but unfortunately they are not able to efficiently transduce HSCs.
AAVs are nonenveloped, single-stranded DNA viruses that replicate only in the presence of
a helper virus, such as adenoviruses or herpes simplex viruses. Nowadays, they are the most
widely used delivery system for in vivo gene therapy due their nonpathogenic behavior and
their capability to overcome the host’s preexisting immunity. The major disadvantage of AAVs
is their low packaging capacity that is incompatible with some therapeutic gene sizes. ZFNs
are the most compact nucleases, and sequences encoding ZFNs can be packaged into these
vectors (110). In the case of the CRISPR/Cas9 tool, only one of the required elements can be
packaged in an AAV. The Streptococcus pyogenes Cas9 can be packaged into an AAV, but the
gRNA sequence should go in a different vector. An alternative to the limited packaging size
of the AAV is the use of the Staphylococcus aureus miniCas9, which perfectly fits the AAV size
with the gRNA sequence. However, the proper definition of the target sites for this miniCas9
is still being improved (87).
IDLVs are currently the preferred tool for transferring genes into HSCs, as they possess certain
advantageous attributes compared to other vectors [reviewed in (38)]. For example, the
preintegration complex of LV is actively translocated into the nucleus and thereby facilitates
efficient transduction of a variety of nondividing cells. In contrast, other viral vectors depend
on the dissolution of the nuclear membrane during mitosis for delivering their cargo into the
target cell nucleus. Consequently, efficient transduction of HSCs can be achieved with IDLVs
after a shorter incubation time in vitro, preserving to some extent the physiological nature of
HSCs and their engraftment potential. IDLVs have successfully delivered ZFNs and homolo‐
gous donor DNA (111). Unfortunately, IDLVs are incompatible with TALENs because highly
homologous TALE repeats often lead to unwanted recombination in cells (112). Moreover, the
production of IDLVs is still the major drawback. The high viral titers needed to efficiently
transduce HSCs are difficult to get, limiting their potential use in many instances.
7. Evidences of gene editing in HSCs and future attempts
Since gene editing technology has started to be used, its applicability to HSCs is being explored.
Either blood disease modeling or new gene therapy approaches have risen from the basics of
gene edition. The development of genome editing technologies based on programmable
nucleases has substantially improved the ability to make precise changes in the genomes of
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the cells compared to small-molecule therapies. However, the gene editing advancement in
hematopoiesis could not be understood without its combination with cell reprogramming
technology, especially iPSCs. The correction by gene editing of patient-specific iPSC has
facilitated the spreading of this technology, allowing the optimization of tools and techniques
on this difficult but easily expandable cell type, which have been then applied to the more
difficult to culture and transfect/transduce HSCs. On the contrary, the current clinical trials
addressed to correct monogenic blood disease by viral vectors, retro and LV, have contributed
to the useful knowledge about these diseases, different delivery systems, and their therapeutic
potentials (Table 2).
The first evidence of gene editing in human hematopoietic progenitors was described in 2002
by Dr. Davis’s group in sickle cell disease (SCD) HSCs (113). SCD is characterized by a single-
point mutation in the seventh codon of the β-globin gene, which means that the site-specific
correction of the mutation would allow for the production of normal hematopoietic cells. By
DNA microinjection, chimeric oligonucleotides designed to direct a site-specific nucleotide
exchange in the human β-globin gene were introduced into CD34+ and Lin- CD38- cells
(purified from umbilical cord blood from healthy donors). Conversion rates of 10% to 15%
were confirmed in Lin- CD38- cells. These levels of correction are enough to correct the
phenotype of the patients in this case, as 10% normal hematopoietic cells are sufficient to render
patients free of SCD. However, human engraftment of edited HSCs in immunodeficient
animals was not tested. The efficacy of gene editing in CD34+ was later improved by the use
of sequence-specific endonucleases. Dr. Naldini’s group was able to identify gene edition in
up to 80% hematopoietic progenitors after transducing cord blood CD34+ with an IDLV
carrying a puromycin-resistant gene together with ZFN targeting CCR5 locus and selecting
them with puromycin (114). The first therapeutic application of gene editing was described 7
years later by the same group. Human HSCs were gene edited at the IL2RG locus, which is
mutated in SCID-X1 patients, by an IDLV delivering a donor template to perform a knock-in
strategy in combination with the electroporation of ZFN mRNAs against the same locus (115).
Since the donor templates carried the GFP reporter cassette alone or together with the
therapeutic IL2RG cDNA, the targeted human hematopoietic could be followed by GFP
expression. GFP could be detected in up to 95% of immunodeficient mice transplanted with
the human progenitors after their gene editing at short term after transplantation. However,
the most significant achievement was the detection of the targeted human hematopoietic cells
in 46% of the transplanted mice at long-term, which meant the targeting of the most primitive
HSCs, the LT-HSCs, and opens up a real potential clinical use of gene editing in HSCs. More
importantly, the IL2RG functionality was restored in T and NK cells derived from the hema‐
topoietic progenitors edited at IL2RG locus. This is the first demonstration of the potential
clinical use of gene edition to treat monogenic blood diseases.
Although the use of large donors to correct patient’s hematopoietic progenitors through a
knock-in or safe harbor approaches have got good preclinical data, its overall efficacy is still
low to be applied in clinical trials. Alternatively, the use of single-stranded oligonucleotides
(ssODNs) for HR has been also explored to perform gene correction due to their high efficacy
and low toxicity. As Proof of concept, gene correction experiments using β-globin ssODNs as
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donors to correct β-thalassemia were performed. Intracellular delivery was done using
biodegradable nanoparticles loaded with triplex-forming peptide nucleic acids (PNAs).
Although low levels of efficacy were reached (<1%), in vivo analysis showed engraftment of
edited cells in NOD-SCID IL2rγ-null mice (116).
Recently, another approach was tested for the introduction of a mutation able to correct SCD
(117). ZFNs were designed to specifically cleave at the β-globin locus with nonrelevant off-
target effects and introduced in CD34+ cells (isolated from umbilical cord or peripheral blood)
by electroporation. Simultaneously, the delivery of an IDLV or DNA oligonucleotide homol‐
ogous donor template allows high levels of gene modification (10–20%) and engraftment in
immunocompromised NSG mice.
The delivery of nucleases using AAV vectors has also demonstrated their feasibility for human
HSCs gene editing. Their low toxicity and relatively easy manufacture, together with the ability
of achieving high recombination frequencies with small homology regions (200 bp), make them
feasible genetic instruments (118). Recent studies showed that AAV serotype 6 was efficient
for the delivery of donor DNAs in human CD34+ Hematopoietic Progenitor Stem Cells (HPSCs)
and can induce Homologous direct Repair (HDR) when used in combination with different
nucleases (119). When AAV6 was used to deliver a GFP cassette flanked by arms homologous
to CCR5 or AAVS1 locus, followed by electroporation with ZFN mRNA, HDR-mediated
insertion at the CCR5 or AAVS1 locus was found in 17% to 26% of cells. Studies in immuno‐
deficient mice showed that modified cells persisted in secondary transplant recipient animals,
meaning that edited cells contained long-term HSCs.
Using a different gene editing approach, β-thalassemia correction has been achieved in a
preclinical study without the need of a donor template (120). This clever approach was based
in the knockout of the BCL11A gene using ZFN to generate INDELs in the mentioned gene.
This gene regulates the transition from fetal globin (γ-globin) to an adult one (β-globin).
Therefore, the disruption of BCL11A gene was able to ameliorate β-thalassemia due to
increasing γ-globin and reducing mutated β-globin level.
The transfer of programmable nucleases into HSCs has been also developed as antiviral
therapies by deleting genes encoding receptors essential to viral entry in the host cells, thus
preventing the infection. The definitive cure of HIV or the achievement of efficient protection
against this virus constitutes one of the biggest goals of modern medicine. Gene therapy can
bring us closer to this purpose by the modification of CCR5, an HIV-1 coreceptor involved in
the entrance of the viral particles in hematopoietic cells. The introduction by electroporation
of specifically designed ZFNs against the CCR5 gene attained 17% of allele disruption. This
ZFN-treated HPSCs were capable of engraft in NOD-SCID IL2rγ-null mice and were able to
produce a polyclonal multilineage progeny where CCR5 disruption was maintained (121).
Moreover, when mice transplanted with ZFN-modified cells were challenged with the HIV-1
virus, the animals were able to maintain the levels of CD4+ T cells throughout their tissues and
showed lower levels of HIV-1 viral load compared to the control animals engrafted with
nonedited HPSCs. In the same direction, other strategies such as the introduction of CCR5-
Specific ZFNs or CCR5-MegaTALEN mRNAs into HPSCs using adenoviral vectors and
electroporation, respectively, have demonstrated the potential of this (118,122).
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Genome editing in HSCs has also been used to model cancer generation and development. For
example, CD34+ cells purified from human cord blood were capable of initiating leukemia in
response to endogenous activated MLL-AF9 or MLL-ENL oncogenes, generated by TALEN-
mediated knock-in (123,124). These cells displayed altered in vitro growth potentials and
induce acute leukemias following transplantation in immunocompromised mice at a mean
latency of 16 weeks. Additionally, the phenotype, morphology, and molecular features of the
induced leukemias were similar to patient leukemic blasts. Consequently, this strategy
provides an experimental platform for prospective studies of mixed lineage leukemia (MLL).
Similarly, the CRISPR/Cas9 system is also applicable to generate some cancer models.
Translocations resembling those described in acute myeloid leukemia and Ewing’s sarcoma
(RUNX1/ETO and EWS/FLI, respectively) were generated in human cell lines and primary
cells. Cas9 nuclease and the specific gRNA were introduced as plasmidic DNA by electropo‐
ration, reaching 4% efficiency in the generation of cancer-like translocations (125).
The application of gene editing to correct or study blood diseases is a growing field, where a
rising number of publications exploring all the potential of this precise gene modification
technology are being generated rapidly. We should be ready for the burst of gene editing in
hematopoiesis.
8. Gene-edited HSCs goes to the clinic
A notable number of phase I/II gene therapy clinical trials have reported evidence of efficacy
and safety for the treatment of various genetic diseases of the blood, including primary
immunodeficiencies, leukodystrophies, thalassemia, and hemophilia. However, some diffi‐
culties are acting as a bottleneck in the clinical approach of gene editing tools. First, the delivery
of genetic tools into hematopoietic progenitors must be improved. Second, an advance in the
culture conditions is needed, given that gene-corrected cells must be present in large enough
quantities to revert the condition and transmit the modification to their progeny. In this way,
some compounds capable of preserving the “stemness” of CD34+ HPSCs are nowadays being
explored, such as SR-1 or UM171, with promising results (126).
Up to now, only one clinical trial worldwide is open to apply gene editing in human HSCs.
The trial is addressing the safety of the transplantation of hematopoietic progenitors, gene
edited for the CCR5 disruption using specific ZFNs, into HIV-1-infected patients. These
patients have undetectable virus but suboptimal CD4+ cell levels. Phase 1 trial is ongoing and
will provide first in human data about the use of gene editing tools (https://goo.gl/M0ZWoB).
9. Other alternative nonhematopoietic sources of HSCs and their edition
Gene edited autologous HSC transplantation (HSCT) approaches remain elusive because of
the difficulty in the culture and expansion of long-term repopulating HSCs ex vivo, as these
protocols still extend for long periods of time to achieve the delivery of the correcting tools
Modern Tools for Genetic Engineering112
and the gene edition itself. An alternative therapeutic strategy is the use of patient-derived
induced pluripotent stem cells (iPSCs) in which disease-causing mutations are corrected by
gene targeting. The development of iPSC-based approach provides an unlimited source of
subject-derived cells that bypasses the main limitation of HSCs-based protocols, as iPSCs
possess properties of self-renewal and pluripotency that are similar to those of embryonic stem
cells (127–129). Moreover, the availability of HSCs is compromised in some situations, and in
this context, easily accessible cell sources, such as skin fibroblasts (130), keratinocytes (131), or
peripheral blood mononuclear cells (132), constitute an advantage for gene editing protocols.
These corrected iPSCs could then be differentiated into the desirable hematopoietic cell for
transplantation into patients to treat the disease (133). Here are some of the most relevant
attempts following this strategy.
Regarding erythroid lineage defects, efforts have focused on β-globin alterations causing β-
thalassemia and SCD. Most of the works have reprogrammed patient-derived cells by
transduction of reprogramming factors, in the case of skin fibroblasts (134–137), or by nucle‐
ofection of amniotic fluid-derived cells (138,139). The gene editing strategy selected was a
knock-in approach, and in the case of β-thalassemia patient-derived iPSCs, the delivery of
TALENs (138,139) or CRISPR/Cas9 (135,139,140) by electroporation achieved specific gene
targeting in human hemoglobin subunit β (HBB) locus, with variable HR rates. More precisely,
in a direct comparison of CRISPR/Cas9 and TALEN, the first ones induced DSBs with greater
efficiency than TALEN, but the second ones mediated a higher homologous gene targeting
efficiency (139). In all the cases, the expression of HBB in colonies formed after clonogenic
progenitor cell assays was comparable to endogenous β-globin allele, but the main challenge
was the complete erythroid differentiation of the edited iPSCs, as embryonic and fetal but not
adult hemoglobin was expressed (135,139). Singularly, Wang et al. reported that gene correc‐
tion without assistant nucleases of iPSC reprogrammed from patient-derived fibroblasts and
then differentiated to hematopoietic progenitors could differentiate in vivo and produce
human β-globin in irradiated SCID mice, although the efficacy of correction was lower than
1% (134).
In the case of SCD, patient-derived fibroblasts were reprogrammed to iPSCs and subsequently
edited by nucleofection of ZFN in a knock-in strategy. Recombination efficacy ranged from
1% to 10%, and as it happened in thalassemia studies, the vast majority of hemoglobin
expression was of the fetal type (136,137).
The gene editing of iPSCs derived from peripheral blood mononuclear cells from pyruvate
kinase deficiency (PKD) patients assisted by TALENs in a knock-in strategy rendered approx‐
imately 10% of efficacy in gene editing, obtaining high numbers of erythroid cells with a
normalized ATP level and a normal metabolic function, providing an approach in which cells
can undergo up to 2×104 -fold expansion to correct metabolic erythroid diseases (9).
In the case of primary immunodeficiencies, the access to BM and thymocyte samples from
untreated patients with SCID is challenging, as these conditions are rare and infants typically
presenting with life-threatening infections require urgent HSCT to survive (141). Different
SCIDs have been addressed by gene editing of patient-derived iPSCs. Chang et al. demon‐
strated that locus-specific correction of the human JAK3 mutation by CRISPR/Cas9-enhanced
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gene targeting of iPSCs derived from skin keratinocytes of SCID patients restored the differ‐
entiation potential of early T-cell progenitors. The strategy used was knock-in and efficacies
ranged from 6% to 73 % of the analyzed clones when using one gRNA and from 0 to 100% of
G418-resistant clones when using two guides. Corrected progenitors were capable of produc‐
ing NK cells and mature T-cell populations expressing a broad TCR repertoire as well as all
hematopoietic lineages. However, after transplantation in NSG mice, the differentiation to all
hematopoietic lineages was not detectable (141).
Human mesenchymal cells from SCID-X1 patients were reprogrammed to iPSCs and after‐
wards corrected by HR assisted by TALENs in the IL-2Rg locus, following also a knock-in
strategy, with an efficiency of 2.6% (142). They used a selection-free approach, as cells bearing
a functional γ-chain show a positive selective advantage (143). The gene editing resulted in
the rescue of T-cell precursors and mature NK cells after long-term differentiation in vitro (142).
In ADA-SCID patients, the protocol was improved to perform reprogramming and gene
targeting together in a one-step procedure that required only a single electroporation in an
attempt to avoid cells to be in culture for several months, which is not compatible for patients
for whom urgent medical intervention is imperative. They obtained 5% corrected iPSCs from
skin biopsies of ADA-SCID patients after gene editing assisted by CRISPR/Cas9 and using
single-stranded corrective oligonucleotide (ssODN) as therapeutic matrix, where the expres‐
sion of corrected ADA mRNA was confirmed (144).
Some works have been performed in X-linked chronic granulomatous disease (X-CGD), being
the selected strategy for gene editing the directed insertion of therapeutic cDNA in the safe
harbor locus AAVS1. The selection of the promoter that drives the expression of the therapeutic
gene seems to be quite important in CGD, as an inappropriate expression of the transgene in
other cellular types, as the stem cell compartment, could lead to an exacerbate reactive oxygen
species (ROS) production and engraftment failure (43,145). Merling et al. have developed a
platform that combines the production of iPSCs derived from patients with the five genetic
forms of CGD with the targeting of AAVS1 safe harbor assisted by ZFNs, resulting in neutro‐
phils and macrophages differentiated from the corrected iPSCs with a restored ROS produc‐
tion and antimicrobial function (146).
TALEN-assisted specific gene correction of RUNX1 gene in iPSCs derived from dermal
fibroblasts from a patient with familial platelet disorder resulted in the restoration of mega‐
karyopoiesis and subsequent maturation of the corrected cells (147). Even in a DNA repair
deficiency syndrome such as Fanconi anemia, with defects in homology-directed DNA repair,
the wild-type cDNA of FANCA was targeted to AAVS1, assisted by ZFNs with an efficiency
of gene targeting up to 4%, rendering disease-free hematopoietic progenitors (108).
Direct reprogramming, meaning the generation of hematopoietic cells or HSCs directly from
nonhematopoietic cells, has been also assayed with only modest or even irreproducible results
(148,149). No data are available related to the combination of gene correction with hemato‐
poietic direct reprogramming.
Taking all these data into account, an iPSC-based approach would provide an unlimited source
of patient-derived corrected cells from which hematopoietic cells could be derived continu‐
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ously, and this approach could serve as a complementary approach to treat patients, for
example, infusions of in vitro-derived autologous T cells to stabilize patients after HSCT (150).
However, proper differentiations of the desirable cellular type, being the generation of real
HSCs the major barrier, and an unsuitable engraftment of corrected cells remain the main
pitfalls for the translation of this technology to the clinics.
10. Overall remarks
Although conventional gene therapy is becoming an alternative therapeutic option, being
considered in some instances before allogeneic BM transplantation therapeutic option, the
development of new tools and strategies to overcome the potential risks associated with the
present ones is an already established challenge in the gene therapy field. Moreover, the precise
correction of the mutation or mutations present in the patient’s cells is the primary objective
of any researcher committed to gene therapy. In this respect, gene editing is clearly an option
to be explored and optimized. The gene editing field is constantly growing and changing. In
the future, both hereditary and acquired diseases may benefit from gene editing strategies
coupled with hematopoietic cell transplantation. As the conventional gene therapy of mono‐
genic disease is the first and most successful clinical therapy involving genetic modification,
the partnership between gene editing and hematopoietic progenitor transplantation will be
one of the widest and effective gene therapies for these types of hematopoietic diseases.
Figure 2. Potential strategies to follow in a HSC gene editing clinical protocol.
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Without any doubts, this traces the origin of a new era in cell and gene therapy and brings us
closer to the aim of accurate site-specific gene editing in patients.
Cell
source
Nuclease Donor Delivery
system
(nuclease/
donor)
Strategy EfficiencyGene therapy Gene edited
HSC
engraftment
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Human
UCB-
CD34+
and Lin-
CD38-
No Chimeric
oligonucleotides
Microinjection Gene
correction
10–15% Modeling point
mutation of sickle-
cell anemia
Not tested (113)
Human
UCB-
CD34+
ZFN CCR5 HA-PGK-
GFP-CCR5 HA
IDLV/IDLV Safe harbor
(CCR5)
0.03–
0.11%
Proof-of-concept Not tested (114)
Human
mobilized
PB-CD34+
No β-Globin
ssODN
PNAs Gene
correction
0.5–1% Proof-of-concept Not tested (175)
Human
mobilized
PB-CD34+
No CCR5 and β-
globin ssODN
PNAs Gene
correction
0.43% Proof-of- concept Yes (in vivo
gene editing
of human
hematopoietic
cells
engrafted in
NSG)
(116)
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UCB-
CD34+
and BM-
CD34+
ZFN HA-PGK-GFP-
HA and HA-
IL2RG-cDNA-
PGK-GFP-HA
mRNA
electroporation/
IDLV
Safe harbor
(AAVS1) and
knock-in
3–11% SCID-X1 patient’s
HSC
Yes (NSG) (115)
Human
mobilized
PB-CD34+
ZFN No mRNA
electroporation
Knockout
(BCL11A)
60–80% β-Thalassemia Not tested (120)
Human
BM-
CD34+
ZFN β-Globin donor
IDLV or ssODN
mRNA
electroporation/
IDLV or
ssODN
electroporation
Gene
correction
30–40% Sickle-cell anemia Yes (NSG) (117)
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Nuclease Donor Delivery
system
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Strategy EfficiencyGene therapy Gene edited
HSC
engraftment
Reference
or fetal
liver
CD34+
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delivery
Human
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PB-CD34+
ZFN No Plasmidic DNA
electroporation
Knockout
(CCR5)
17% HIV protection Yes (NSG) (121)
Human
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PB-CD34+
ZFN No Adenoviral
vector
Knockout
(CCR5)
26–31% HIV protection Yes (NSG) (176)
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PB-CD34+
CRISPR/
Cas9
No Plasmidic DNA
electroporation
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(B2M and
CCR5)
26.8% Hypoimmunogenic
cells for
transplantation
and HIV protection
Yes (NSG) (177)
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PB-CD34+
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TALEN
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AAV
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mediated by
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CRISPR/
Cas9
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(RUNX1/
ETO)
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Cancer modeling Not tested (180)
Human
UCB-
CD34+
TALEN MLL HA-
cDNA(AF9,
ENL2 or ENL7)-
IRES-
NeonGreen-
MLL HA
Plasmidic DNA
electroporation
Chromosomal
translocation
(MLL-AF9,
MLL-ENL2,
and MLL-
ENL7)
9% Cancer modeling Yes (NSG) (123)
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Table 2. Present results in the gene editing of hematopoietic stem cells.
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